Anzeige
Meldung des Tages: Der Antimon-Boom ist da – und Antimony Resources (ATMY) liefert die hochgradigste Entdeckung Nordamerikas

Trevi Therapeutics Aktie News

Aktie
WKN:  A2PHHF ISIN:  US89532M1018 US-Symbol:  TRVI Branche:  Biotechnologie Land:  USA
11,18 $
-0,03 $
-0,27%
9,6095 € 09.01.26
Depot/Watchlist
Marktkapitalisierung *
975,56 Mio. €
Streubesitz
-
KGV
-9,16
Index-Zuordnung
-

Trevi Therapeutics News

01.05.25 - PR Newswire
Trevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025
Trevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025 PR Newswire
18.03.25 - PR Newswire
Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates
Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates PR Newswire
11.03.25 - PR Newswire
Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025
Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025 PR Newswire
10.03.25 - PR Newswire
Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough
Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough PR Newswire
09.03.25 - PR Newswire
Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough
Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic ...
27.02.25 - PR Newswire
Trevi Therapeutics to Participate in Upcoming March Investor Conferences
Trevi Therapeutics to Participate in Upcoming March Investor Conferences PR Newswire
25.02.25 - PR Newswire
Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough
Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough PR Newswire
30.01.25 - PR Newswire
Trevi Therapeutics to Participate in Upcoming February Investor Conferences
Trevi Therapeutics to Participate in Upcoming February Investor Conferences PR Newswire

Newssuche

Videos

newspaper
09.01.26
FEIERABEND-​TRADING
Börsentäglich um 18.30 Uhr startet unser FEIERABEND-​TRADING live! René Wolfram, der Drittplatzierte ... Mehr »